Skip to main content
Signal8
Launch Terminal

Grace Therapeutics, Inc. (GRCE)

Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada. The company's most advanced experimental treatment is GTX-104, an intravenous infusion designed to address subarachnoid hemorrhage. Its development pipeline further includes GTX-102, an oral mucosal betamethasone spray intended for the management of ataxia-telangiectasia, and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. Established in 2002, the enterprise previously operated under the name Acasti Pharma Inc., before officially adopting Grace Therapeutics, Inc. in October 2024. The company's main offices are located in Princeton, New Jersey.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Grace Therapeutics, Inc. logo

Grace Therapeutics, Inc.

NASDAQ:GRCEHealthcare
+0.00%$1.94
AH$1.94+0.00%vs close
Mkt Cap$40.81M
Float17.11M
O/S21.04M
Vol
$ Vol
RVOL
Inst Own18.3%
Earnings
Dilution
Grace Therapeutics, Inc. logoNASDAQ:GRCE$1.94+0.00%
Phase Distribution
10 lead-sponsored trials·2 active·6 completed
Phase 13
Phase 22
Phase 33
Not applicable1
Not reported1
(2 more as collaborator)
Status Overview
Recruiting1
Active, not recruiting1
Completed6
Unknown2

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 3
    Completed

    A Phase 3 STudy of CaPRe in LOwering Very hiGh TriglYcerides (TRILOGY 2)

    CaPre, Placebo

    Hypertriglyceridemia

    Enrollment
    278
    Start
    Feb 2018
    Primary Completion
    Sep 2019
    Completion
    Jan 2020
    NCT03361501
  • Phase 3
    Completed

    A Phase 3 STudy of CaPRe In LOwering Very hiGh TriglYcerides (TRILOGY 1)

    CaPre, Placebo

    Hypertriglyceridemia

    Enrollment
    256
    Start
    Jan 2018
    Primary Completion
    Jul 2019
    Completion
    Nov 2019
    NCT03398005
  • Phase 3
    Active, not recruiting

    Safety and Tolerability of GTX-104 Compared with Oral Nimodipine in Patients with ASAH

    GTX-104, Nimotop 30 MG Oral Capsule

    Aneurysmal Subarachnoid Hemorrhage (aSAH)

    Enrollment
    100
    Start
    Oct 2023
    Primary Completion
    Dec 2024est.
    Completion
    Dec 2024est.
    NCT05995405
  • Phase 2
    Completed

    TRIal For Efficacy of Capre on hyperTriglyceridemiA

    CaPre (TM), CaPre (TM)

    Hypertriglyceridemia

    Enrollment
    387
    Start
    Sep 2011
    Primary Completion
    Jun 2014
    Completion
    Aug 2014
    NCT01455844
  • Phase 2
    Completed

    Assess the Safety and Efficacy of NKPL66 (CaPre™) in the Treatment of Mild-to-high Hypertriglyceridemia

    Lipid Lowering Medication

    Hypertriglyceridemia

    Enrollment
    289
    Start
    Dec 2011
    Primary Completion
    May 2013
    Completion
    Sep 2013
    NCT01516151
  • Phase 1
    Completed

    Relative Bioavailability of Intravenous GTX-104 Compared to Oral Nimodipine Capsules in Healthy Subjects

    GTX-104, Nimodipine Capsules

    Aneurysmal Subarachnoid Hemorrhage

    Enrollment
    58
    Start
    Aug 2021
    Primary Completion
    Feb 2022
    Completion
    Feb 2022
    NCT05418348
  • Phase 1
    Unknown status

    Single-dose to Evaluate the Pharmacokinetics of GTX-101 and Subcutaneous Injectable Bupivacaine in Healthy Subjects

    GTX-101, Bupivacaine HCl subcutaneous injection

    Postherpetic Neuralgia

    Enrollment
    48
    Start
    Jul 2022
    Primary Completion
    Aug 2022
    Completion
    May 2023est.
    NCT05517486
  • Phase 1
    Unknown status

    Comparative Bioavailability of Betamethasone Oral Solution Metered Spray (GTX-102) in Healthy Subjects

    GTX-102 medium dose fast Period 1 and Period 2, GTX-102 medium dose slow Period 1 and Period 2

    Ataxia Telangiectasia

    Enrollment
    48
    Start
    Sep 2022
    Primary Completion
    Nov 2022
    Completion
    May 2023est.
    NCT05531890
  • Not applicable
    Recruiting

    Tympanoseal Clinical Study

    Tympanoseal

    Tympanic Membrane Perforation

    Enrollment
    45
    Start
    Jan 2024
    Primary Completion
    Apr 2026est.
    Completion
    Apr 2026est.
    NCT05849844
  • Not reported
    Completed

    Tympanoseal (Tympanic Membrane Device) Clinical Study

    Tympanoseal

    Tympanic Membrane Perforation

    Enrollment
    25
    Start
    Oct 2016
    Primary Completion
    Sep 2021
    Completion
    Sep 2021
    NCT02918942
Search ClinicalTrials.gov for “Grace Therapeutics”